text: Is Sanofi's Stock a Buy? | The Motley Fool
  With new promising results for its diabetes drug, is Sanofi a good investment right now?
  Dec 4, 2019 at 11:05AM
  Investors looking for a large-cap pharmaceutical investment have a number of options to choose from. One of them is Sanofi (NASDAQ:SNY), a company with a fairly diverse drug portfolio that has been getting plenty of attention due to its diabetes treatments, a market that's especially lucrative right now.
  In 2018, Lantus brought in $3.95 billion for Sanofi. However, this figure has fallen by more than $1.17 billion from the previous year as competition from other diabetes drug makers, such as Novo Nordisk (NYSE:NVO), continues to ramp up. So Sanofi has been working on a couple of next-generation diabetes treatments to shore up its floundering Lantus sales.